November 7, 2019
Talaris Therapeutics Presents Data Supporting Potential of FCR001 to Prevent Recurrence of Kidney-Related Autoimmune Disease in Kidney Transplant Recipients
BOSTON & LOUISVILLE, Ky.–(BUSINESS WIRE)–Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential…